Literature DB >> 6225745

Anterior chamber-associated immune deviation induced by TNP-splenocytes (TNP-ACAID). II. Suppressor T-cell networks.

J C Waldrep, H J Kaplan.   

Abstract

Injection of trinitrophenyl (TNP)-modified splenocytes (TNP-Sp) into the anterior chamber (AC) of the eye results in systemic tolerance to TNP, a phenomenon termed "AC-associated immune deviation" or "TNP-ACAID". The systemic tolerance of TNP-ACAID is mediated by splenic suppressor T cells (Ts) that comprise an immunoregulatory network made up of two functionally distinct subsets (Ts-I and Ts-II). Ts-I is antigen-specific and cyclophosphamide (Cy)-sensitive, and requires a Cy-sensitive auxiliary cell. Conversely, Ts-II is antigen-nonspecific and Cy-resistant, and requires a TNP-derived accessory macrophage. Suppression via Ts-II is demonstrated only when Ts-I cells are inactivated functionally by Cy. Ts-II cells are regulated by T cells isolated from splenocytes containing active Ts-I suppressors. This contrasuppressive activity is mediated by Ts-I, or perhaps by a third T-cell subpopulation. The relationship between the two suppressor pathways in TNP-ACAID is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225745

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  3 in total

1.  Role of suppressor T cells in herpes simplex virus-induced immune deviation.

Authors:  J A Whittum; J Y Niederkorn; J P McCulley; J W Streilein
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

2.  Hamster Greene melanoma in the rabbit eye: immunosuppressive treatment to improve this tumor model.

Authors:  I de Waard-Siebinga; J L van Delft; D de Wolff-Rouendaal; M Jager
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-11       Impact factor: 3.117

3.  Regulation of the antibody response to type III pneumococcal polysaccharide by contrasuppressor T cells.

Authors:  H Braley-Mullen
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.